Inhibitors of IL-6 and its receptors, such as Tocilizumab, have been approved by the FDA for treating chimeric antigen receptor (CAR)-T-cell mediated cytokine release syndrome (CRS), and have been proposed as a new therapeutic strategy for other types of cytokine wave including sepsis [31]. This evidence concerns the gene IL6 and congenital rubella syndrome.